TriSalus Life Sciences(TLSI.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
TriSalus Life Sciences
TLSI.US
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
1.911 T
TLSI.USMarket value -Rank by Market Cap -/-

Financial Score

15/01/2026 Update
B
BiotechnologyIndustry
Industry Ranking42/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE300.38%A
    • Profit Margin-98.45%E
    • Gross Margin83.52%A
  • Growth ScoreB
    • Revenue YoY49.52%A
    • Net Profit YoY-20.49%D
    • Total Assets YoY32.70%A
    • Net Assets YoY-30.79%E
  • Cash ScoreB
    • Cash Flow Margin-56.77%D
    • OCF YoY49.52%A
  • Operating ScoreA
    • Turnover1.26A
  • Debt ScoreE
    • Gearing Ratio173.29%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    He Yi responded to users' expectations for the CZ role: Diversity needs to be respected, and being down-to-earth does not prevent one from looking up at the stars.

    In response to a user's opinion that "CZ should not only focus on creating memes in the cryptocurrency circle, but should devote himself to future technologies such as AI, human regeneration, and Mars exploration," He Yi responded on social media that diversity itself is an important value of the industry and should be fully respected.

    CoinLive·
    US
    AI
    +2.58%
    CoinLive·
    US
    AI
    +2.58%

    House dust mite disease market shows steady growth at 3.5% CAGR (2025-2034) due to rising allergic conditions, with focus on allergen-specific immunotherapies like sublingual tablets.

    The market for treating house dust mite disease is steadily growing due to the increasing global presence of allergic rhinitis and asthma associated with indoor allergens. The rise in adoption of allergen-specific immunotherapies, such as sublingual tablets, is broadening treatment choices. This growth is fueled by the increasing number of individuals affected by these conditions.

    Unusual Whales·
    Unusual Whales·

    10 clinical trials to watch in the first half of 2026

    The biotechnology industry is starting 2026 with renewed momentum, marked by increased dealmaking and rising market values for successful biotechs. A key stock index for biotech surged by a third last year, reflecting a resurgence of generalist investors. The emergence of a trillion-dollar drugmaker highlights the sector's growth, driven by promising clinical trial results. The first half of 2026 will feature 10 significant clinical trials in areas such as obesity, infectious diseases, and rare disorders, which are anticipated to attract further investment and interest.

    biopharmadive·
    US
    RARE
    -0.17%
    biopharmadive·
    US
    RARE
    -0.17%

    Barclays Research: Humanoid robotics industry expected to hit $200 billion market by 2035 due to advancements in AI tech.

    Barclays Research has released a report predicting that the humanoid robotics industry will reach a $200 billion market by 2035, driven by advancements in AI technology. The report highlights the shift of humanoid robots from experimental to practical applications, particularly in manufacturing and healthcare. Significant improvements in AI reasoning, actuator technology, and battery systems have resulted in a 30-fold decrease in production costs over the past decade, facilitating this industry transformation.

    Unusual Whales·
    Unusual Whales·

    Landsbankinn hf. announces successful covered bond offering, raising X amount.

    In the latest update, it was reported that the number of new COVID-19 cases has increased by [number] in the past 24 hours, bringing the total number of cases to [number]. Additionally, [number] new deaths were recorded, raising the death toll to [number]. The authorities have emphasized the importance of following safety protocols such as wearing masks and practicing social distancing to curb the spread of the virus. Testing and vaccinations continue to be crucial in the ongoing battle against the pandemic.

    Unusual Whales·
    Unusual Whales·
    © 2026 Longbridge｜Disclaimer